## Cynthia G Whitney

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2900878/publications.pdf Version: 2024-02-01

		840119	642321
23	9,132	11	23
papers	citations	h-index	g-index
23	23	23	10193
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clinical Infectious Diseases, 2007, 44, S27-S72.	2.9	5,203
2	Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. American Journal of Respiratory and Critical Care Medicine, 2019, 200, e45-e67.	2.5	2,013
3	Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infectious Diseases, The, 2015, 15, 301-309.	4.6	638
4	U.S. Hospitalizations for Pneumonia after a Decade of Pneumococcal Vaccination. New England Journal of Medicine, 2013, 369, 155-163.	13.9	455
5	Effects of Vaccination on Invasive Pneumococcal Disease in South Africa. New England Journal of Medicine, 2014, 371, 1889-1899.	13.9	308
6	Revisiting Pneumococcal Carriage by Use of Broth Enrichment and PCR Techniques for Enhanced Detection of Carriage and Serotypes. Journal of Clinical Microbiology, 2010, 48, 1611-1618.	1.8	234
7	Vital Signs: Deficiencies in Environmental Control Identified in Outbreaks of Legionnaires' Disease — North America, 2000–2014. Morbidity and Mortality Weekly Report, 2016, 65, 576-584.	9.0	143
8	Early impact of 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis—Burkina Faso, 2014–2015. Journal of Infection, 2018, 76, 270-279.	1.7	27
9	Postmortem investigations and identification of multiple causes of child deaths: An analysis of findings from the Child Health and Mortality Prevention Surveillance (CHAMPS) network. PLoS Medicine, 2021, 18, e1003814.	3.9	24
10	Impact of 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis, Burkina Faso, 2016–2017. Journal of Infectious Diseases, 2019, 220, S253-S262.	1.9	21
11	Triumph of Pneumococcal Conjugate Vaccines: Overcoming a Common Foe. Journal of Infectious Diseases, 2021, 224, S352-S359.	1.9	18
12	Estimating the economic burden of pneumococcal meningitis and pneumonia in northern Ghana in the African meningitis belt post-PCV13 introduction. Vaccine, 2021, 39, 4685-4699.	1.7	8
13	Population impact and effectiveness of sequential 13-valent pneumococcal conjugate and monovalent rotavirus vaccine introduction on infant mortality: prospective birth cohort studies from Malawi. BMJ Global Health, 2020, 5, e002669.	2.0	5
14	Evaluation of pneumococcal meningitis clusters in Burkina Faso and implications for potential reactive vaccination. Vaccine, 2020, 38, 5726-5733.	1.7	5
15	Serotype-specific effectiveness against pneumococcal carriage and serotype replacement after ten-valent Pneumococcal Conjugate Vaccine (PCV10) introduction in Pakistan. PLoS ONE, 2022, 17, e0262466.	1.1	5
16	Vaccination and vacci-notions: Understanding the barriers and facilitators of COVID-19 vaccine uptake during the 2020-21 COVID-19 pandemic. Public Health in Practice, 2022, 3, 100276.	0.7	5
17	Methods for estimating the direct and indirect effect of 10 valent pneumococcal vaccine on nasopharyngeal carriage in children under 2 years in Matiari, Pakistan. MethodsX, 2021, 8, 101357.	0.7	4
18	Pneumococcal Carriage in Burkina Faso After 13-Valent Pneumococcal Conjugate Vaccine Introduction: Results From 2 Cross-sectional Population-Based Surveys. Journal of Infectious Diseases, 2021, 224, S258-S266.	1.9	4

#	Article	IF	CITATIONS
19	Improving Capture of Vaccine History: Case Study from an Evaluation of 10-Valent Pneumococcal Conjugate Vaccine Introduction in Kenya. American Journal of Tropical Medicine and Hygiene, 2016, 94, 1400-1402.	0.6	3
20	Characterization of pneumococcal meningitis before and after introduction of 13-valent pneumococcal conjugate vaccine in Niger, 2010–2018. Vaccine, 2020, 38, 3922-3929.	1.7	3
21	Direct effects of pneumococcal conjugate vaccines among children in Latin America and the Caribbean. Lancet Infectious Diseases, The, 2021, 21, 306-308.	4.6	3
22	High Prevalence of Vaccine-Type Infections Among Children with Pneumococcal Pneumonia and Effusion After 13-Valent Pneumococcal Conjugate Vaccine Introduction in the Dominican Republic. Journal of Infectious Diseases, 2021, 224, S228-S236.	1.9	2
23	Antimicrobial Resistance in Pneumococcal Carriage Isolates from Children under 2 Years of Age in Rural Pakistan. Microbiology Spectrum, 2021, 9, e0101921.	1.2	1